Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Painreform Ltd. (PRFX)
:PRFX
Holding PRFX?
Track your performance easily
PRFX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.73 - $61.24
Previous CloseN/A
Volume49.01K
Average Volume (3M)4.77M
Market Cap
$2.84M
Enterprise ValueN/A
Total Cash (Recent Filing)$40.00K
Total Debt (Recent Filing)$4.52M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 28, 2025EPS Estimate
-7.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.29
Shares Outstanding874,862
10 Day Avg. Volume140,323
30 Day Avg. Volume4,765,643
Standard Deviation0.22
R-Squared0.02
Alpha-0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
PainReform News
PremiumCompany Announcements
PainReform Ltd. Gains $3.17 Million from Warrant Exercise
PremiumCompany Announcements
PainReform Faces Setback in Phase 3 Trial for PRF-110Bulls Say, Bears Say
Bulls Say
Clinical OutcomesPatients were found to experience proper wound healing with no abnormalities in scar formation.
Product DevelopmentPRF-110 is being developed to compete with Exparel and Zynrelef, the two leading nonopioid therapies for post-operative pain.
Safety And EfficacyThe pharmacokinetic evaluations showed levels of ropivacaine in the blood were 10x lower than the levels required for toxic exposure, further supporting PRF-110’s safety.
Bears Say
Capital RequirementsPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Financial PerformanceThere is uncertainty about PainReform's ability to continue the development of PRF-110 due to capital constraints and lower revenue potential.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
---
Ownership Overview
―
Insiders
0.22%
Mutual Funds
― Other Institutional Investors
99.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PRFX FAQ
What was Painreform Ltd.’s price range in the past 12 months?
Painreform Ltd. lowest stock price was $1.73 and its highest was $61.24 in the past 12 months.
What is Painreform Ltd.’s market cap?
Painreform Ltd.’s market cap is $2.84M.
When is Painreform Ltd.’s upcoming earnings report date?
Painreform Ltd.’s upcoming earnings report date is Feb 28, 2025 which is in 41 days.
How were Painreform Ltd.’s earnings last quarter?
Painreform Ltd. released its earnings results on Nov 12, 2024. The company reported -$18.96 earnings per share for the quarter, the consensus estimate of -$18.96 by $0.
Is Painreform Ltd. overvalued?
According to Wall Street analysts Painreform Ltd.’s price is currently Overvalued.
Does Painreform Ltd. pay dividends?
Painreform Ltd. does not currently pay dividends.
What is Painreform Ltd.’s EPS estimate?
Painreform Ltd.’s EPS estimate is -7.68.
How many shares outstanding does Painreform Ltd. have?
Painreform Ltd. has 874,862 shares outstanding.
What happened to Painreform Ltd.’s price movement after its last earnings report?
Painreform Ltd. reported an EPS of -$18.96 in its last earnings report, expectations of -$18.96. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Painreform Ltd.?
Currently, no hedge funds are holding shares in PRFX
---
Company Description
Painreform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
---
Technical Analysis
Brainstorm Cell Therapeutics
―
Corbus Pharmaceuticals
―
ESSA Pharma
―
Evoke Pharma
―
Sonoma Pharmaceuticals
―
Assertio Therapeutics
―
---